Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 21, 24 | -0.18 Increased by +95.38% | -0.48 Increased by +62.50% |
| Feb 12, 24 | -0.30 Decreased by -233.33% | -0.31 Increased by +3.23% |
| Nov 13, 23 | -0.43 Decreased by -290.91% | -0.11 Decreased by -290.91% |
| Aug 11, 23 | -0.54 Decreased by -440.00% | -0.09 Decreased by -500.00% |
| Jun 23, 23 | -3.90 Decreased by -4.23 K% | -0.84 Decreased by -364.29% |
| Feb 14, 23 | -0.09 Increased by +18.18% | -0.15 Increased by +40.00% |
| Nov 14, 22 | -0.11 Decreased by -266.67% | - |
| Aug 11, 22 | -0.10 Decreased by -25.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Increased by +100.00% | -3.17 M Increased by +89.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.39 M Increased by +38.52% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.72 M Increased by +24.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -4.02 M Increased by +11.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | -32.00 K Decreased by -346.15% | -29.09 M Decreased by -623.56% | Increased by +90.90 K% Increased by +393.95% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.89 M Decreased by -2.94% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.93 M Decreased by -602.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 32.00 K Decreased by -72.17% | -4.52 M Decreased by -45.09% | Decreased by -14.14 K% Decreased by -421.43% |